Aquestive Therapeutics
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies.
Investor website: https://aquestive.com/
We don’t have processed documents for Aquestive Therapeutics yet, so the AI assistant isn’t available on this page.
About
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. With proprietary technologies like PharmFilm® and AdrenaVerse™, we’re advancing patient-friendly alternatives to inconvenient or invasive therapies, including investigational treatments for anaphylaxis and potentially alopecia areata. Our expertise spans the full product lifecycle, from formulation to commercialization, with four commercialized products marketed by our licensees in the U.S. and around the world. We have the expertise to manufacture and package a wide range of pharmaceutical products, including oral films, creams, and lotions, for our contract licensees and customers. Since the inception of the Company, we have been committed to our purpose: developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies.
Verified company data
- Cash position
- $110.7 million
- Shares outstanding
- 99,723,635
- Projects
- ["Anaphylm™ (dibutepinephrine) sublingual film\nPotential Indication\nType 1 allergic reactions, including anaphylaxis\nPre-ClinicalPhase 1Phase 2Phase 3\nAn oral film formulation using Aquestive’s novel prodrug of epinephrine for the emergency treatment of Type 1 allergic reactions, including anaphylaxis.\n[Learn more](https://aquestive.com/anaphylm)","AQST-108 (epinephrine) topical gel\nPotential Indication\n(multiple potential indications)\nPre-ClinicalPhase 1Phase 2Phase 3","Libervant® (diazepam) buccal film\nPotential Indication\nAcute repetitive seizures / cluster seizures\nPre-ClinicalPhase 1Phase 2Phase 3\nAn oral film formulation of diazepam being developed as a rescue therapy for intermittent, stereotypic episodes of frequent seizure activity (also known as seizure clusters) in patients with epilepsy.\n[Learn more](https://aquestive.com/libervant)"]
- Leadership
- Dan Barber (Director Aquestive, President and Chief Executive Officer), Peter Boyd (Chief People Officer), Melina T. Cioffi, Pharm.D. (Senior Vice President – Regulatory Affairs), Matthew W. Davis, M.D., RPh (Chief Development Officer), Matthew Greenhawt, M.D. (Chief Medical Officer), Cassie Jung (Chief Operating Officer), Sherry Korczynski (Chief Commercial Officer), Ernie Toth (Chief Financial Officer), Thomas A. Zalewski (Chief Legal Officer and Chief Compliance Officer), Gregory B. Brown, M.D. (Chair of the Board, Aquestive Director and Co-founder of HealthCare Royalty Partners), John Cochran (Aquestive Director, Partner at Bratton Capital Management L.P., Partner and Chief Operating Officer of Crestline Investors, Inc.), Abigail L. Jenkins (Aquestive Director, former Director and President & CFO of Gamida Cell Ltd.), Julie Krop, M.D. (Aquestive Director, and Chief Medical Officer of DiaMedica Therapeutics, Inc.), Timothy E. Morris (Aquestive Director, and Chief Operating Officer of Humanetics Corporation), Marco Taglietti, M.D. (Aquestive Director, and Chief Executive Officer of NanoNewron), David Bernstein, M.D. (Professor Emeritus of Medicine in the Division of Immunology and Allergy at the University of Cincinnati College of Medicine), Carlos Camargo, M.D. (Professor of Emergency Medicine, Medicine, and Epidemiology at Harvard University), David M. Fleischer, M.D. (Section Head of Allergy & Immunology at Children’s Hospital Colorado), David BK Golden, M.D. (Associate Professor of Medicine at Johns Hopkins), Ruchi Gupta, M.D. MPH (Professor of Pediatrics and Medicine at Northwestern University), Jay Lieberman, M.D. (Associate Professor at the University of Tennessee Health Science Center), John Oppenheimer, M.D. (Director of Clinical Research at Pulmonary and Allergy Associates)
Verified data last updated: